Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707545 | 1.00 | KDM4E (1.00) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL30827199 | 1.00 | KDM4E (1.00) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL3557840 | 0.94 | KDM4E (0.89) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL13563344 | 0.90 | MEN1 (0.81) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL1697544 | 0.82 | ALDH1A1 (0.69) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL29884110 | 0.82 | ALDH1A1 (0.69) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL9575208 | 0.81 | KDM4E (0.68) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL13070473 | 0.81 | MEN1 (0.68) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL9812510 | 0.81 | MEN1 (0.68) | KDM4EMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL13518256 | 0.81 | ALDH1A1 (0.68) | KDM4EMEN1ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233645-A | Method for preparing tri-substituted cyclopentene by MBH/Wittig domino reaction of vinylon insertion | 浙江大学 | 2020-06-05 | — | — | CN | claimed |
| EP-2879675-B1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | UNIV DUKE (US) | 2019-11-13 | — | — | EP | claimed |
| US-20180186885-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-05 | — | — | US | claimed |
| WO-2016205551-A2 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| WO-2016205566-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | claimed |
| EP-2494865-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | Aeon Medix Inc. (KR) | 2012-09-05 | — | — | EP | claimed |
| WO-2011027971-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | 주식회사이언메딕스 (KR) | 2011-03-10 | — | — | WO | claimed |
| JP-2011506455-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
| EP-2231147-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009076170-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-02-12 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250290915-A1 | METHOD FOR PREDICTING RESPONSIVENESS TO THERAPY | Cancertain Limited (GB) | 2025-09-18 | — | — | US | disclosed |
| EP-1207162-B1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | UBE INDUSTRIES (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1207162-A1 | 7a-alkoxy-4H-pyrano-[3,2-d]-oxazol-2(3H)-one and process for producing the same | Ube Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
| US-4014889-A | Process for preparing ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | KDM4E 714/4885MEN1 2187/4885ALDH1A1 379/4885 |
| US-20260041767-A1 | METHODS OF IMPROVING CELLULAR THERAPY WITH ORGANELLE COMPLEXES | TFAM, FIS1, TUFM | KDM4E 2587/4885MEN1 3840/4885ALDH1A1 4231/4885 |
| US-20020072612-A1 | 7a-alkoxy-4H-pyrano [3,2-d] -oxazol-2 (3H) -one and process for producing the same | ACSL1, ACSL4, ACSL3 | KDM4E 2201/4885MEN1 4677/4885ALDH1A1 11/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | KDM4E 1024/4885MEN1 2299/4885ALDH1A1 247/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | KDM4E 955/4885MEN1 2034/4885ALDH1A1 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.